These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24091918)

  • 1. Cell-penetrating fusion peptides OD1 and OD2 interact with Bcr-Abl and influence the growth and apoptosis of K562 cells.
    Wang HX; Xiao H; Zhong L; Tao K; Li YJ; Huang SF; Wen JP; Feng WL
    Mol Cell Biochem; 2014 Jan; 385(1-2):311-8. PubMed ID: 24091918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of bcr-abl in human leukemic cells with a coiled-coil protein delivered by a leukemia-specific cell-penetrating Peptide.
    Bruno BJ; Lim CS
    Mol Pharm; 2015 May; 12(5):1412-21. PubMed ID: 25858426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Purification of TAT-CC-HA protein under native condition, and its transduction analysis and biological effects on BCR-ABL positive cells.
    Huang Z; Ji M; Peng Z; Huang S; Xiao Q; Li C; Zeng J; Gao M; Feng W
    Biomed Pharmacother; 2011 Jun; 65(3):183-92. PubMed ID: 21641753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cloning, expression, purification and functional characterization of the oligomerization domain of Bcr-Abl oncoprotein fused to the cytoplasmic transduction peptide.
    Huang SF; Liu DB; Zeng JM; Xiao Q; Luo M; Zhang WP; Tao K; Wen JP; Huang ZG; Feng WL
    Protein Expr Purif; 2009 Apr; 64(2):167-78. PubMed ID: 19041400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
    Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z
    Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization.
    Huang ZL; Gao M; Ji MS; Tao K; Xiao Q; Zhong L; Zeng JM; Feng WL
    Amino Acids; 2013 Feb; 44(2):461-72. PubMed ID: 22782217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib restores VASP activity and its interaction with Zyxin in BCR-ABL leukemic cells.
    Bernusso VA; Machado-Neto JA; Pericole FV; Vieira KP; Duarte AS; Traina F; Hansen MD; Olalla Saad ST; Barcellos KS
    Biochim Biophys Acta; 2015 Feb; 1853(2):388-95. PubMed ID: 25450971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cytotoxicity of a Grb2-SH3 inhibitor in Bcr-Abl positive K562 cells.
    Ye YB; Lin JY; Chen Q; Liu F; Chen HJ; Li JY; Liu WQ; Garbay C; Vidal M
    Biochem Pharmacol; 2008 Jun; 75(11):2080-91. PubMed ID: 18455151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved coiled-coil design enhances interaction with Bcr-Abl and induces apoptosis.
    Dixon AS; Miller GD; Bruno BJ; Constance JE; Woessner DW; Fidler TP; Robertson JC; Cheatham TE; Lim CS
    Mol Pharm; 2012 Jan; 9(1):187-95. PubMed ID: 22136227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
    Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTPROt inactivates the oncogenic fusion protein BCR/ABL and suppresses transformation of K562 cells.
    Motiwala T; Majumder S; Ghoshal K; Kutay H; Datta J; Roy S; Lucas DM; Jacob ST
    J Biol Chem; 2009 Jan; 284(1):455-464. PubMed ID: 18997174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands.
    Shibata N; Miyamoto N; Nagai K; Shimokawa K; Sameshima T; Ohoka N; Hattori T; Imaeda Y; Nara H; Cho N; Naito M
    Cancer Sci; 2017 Aug; 108(8):1657-1666. PubMed ID: 28556300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway.
    Huang R; Liu H; Chen Y; He Y; Kang Q; Tu S; He Y; Zhou X; Wang L; Yang J; Wu A; Li Y
    Oncol Rep; 2018 Jan; 39(1):119-128. PubMed ID: 29192326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.
    Bandyopadhyay G; Biswas T; Roy KC; Mandal S; Mandal C; Pal BC; Bhattacharya S; Rakshit S; Bhattacharya DK; Chaudhuri U; Konar A; Bandyopadhyay S
    Blood; 2004 Oct; 104(8):2514-22. PubMed ID: 15226183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
    Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
    Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disrupting BCR-ABL in combination with secondary leukemia-specific pathways in CML cells leads to enhanced apoptosis and decreased proliferation.
    Woessner DW; Lim CS
    Mol Pharm; 2013 Jan; 10(1):270-7. PubMed ID: 23211037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
    Pytel D; Wysocki T; Majsterek I
    Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced and selective killing of chronic myelogenous leukemia cells with an engineered BCR-ABL binding protein and imatinib.
    Constance JE; Woessner DW; Matissek KJ; Mossalam M; Lim CS
    Mol Pharm; 2012 Nov; 9(11):3318-29. PubMed ID: 22957899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
    Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
    Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting SKP2/Bcr-Abl pathway with Diosmetin suppresses chronic myeloid leukemia proliferation.
    Liu Y; Shao Z; Liao Y; Xia X; Huang C; He J; Hu T; Yu C; Jiang L; Liu J; Huang H
    Eur J Pharmacol; 2020 Sep; 883():173366. PubMed ID: 32679184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.